This early phase I trial studies how well loratadine works in reducing granulocyte-colony stimulating factor (G-CSF) induced bone pain in patients with multiple myeloma who are undergoing stem cell mobilization. Loratadine is an antihistamine that may help to reduce or control bone pain during the process of stem cell collection in patients with multiple myeloma.
Patient must be able to provide informed consent
Patients with confirmed diagnosis of multiple myeloma
Able to swallow and retain oral medication
All ethnic groups are eligible
Non-English speaking person
Patients undergoing haploidentical allogeneic hematopoietic stem cell transplant
Known allergies, hypersensitivity, or intolerance to any of the study medications, excipients, or similar compounds
Any medical complications or conditions that would, in the investigator's judgement, interfere with full participation in the study
Rutgers, The State University of New Jersey
Lead sponsor
Rutgers Cancer Institute of New Jersey
Sponsor institution
National Cancer Institute (NCI)
Collaborator